MedPath

Gamida Cell -Teva Joint Venture Ltd.

Ownership
Private
Employees
-
Market Cap
-
Website

Clinical Trials

3

Active:2
Completed:1

Trial Phases

1 Phases

Phase 2:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Phase 2
1 (100.0%)

Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy

Phase 2
Completed
Conditions
Hematologic Malignancies
Acute Myeloid Leukemia
Lymphoid Leukemia
Chronic Myeloid Leukemia
Hodgkin's Disease
Non-Hodgkin's Lymphoma
Myelodysplastic Syndromes
Interventions
Drug: StemEx®
First Posted Date
2007-05-04
Last Posted Date
2015-07-10
Lead Sponsor
Gamida Cell -Teva Joint Venture Ltd.
Target Recruit Count
101
Registration Number
NCT00469729
Locations
🇺🇸

UCLA's Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

🇺🇸

Children's Hospital of Orange County, Orange, California, United States

🇺🇸

The Children's Hospital, B115, University of Colorado Health Sciences Center, Aurora, Colorado, United States

and more 27 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.